RBOT vs ISRG vs MASI vs SSYS vs TMCI

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -27. 1% for Masimo Corporation (MASI). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Masimo Corporation is actually cheaper at 32.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Masimo Corporation (MASI) is the lower-risk stock at 0.

63β versus Treace Medical Concepts, Inc. 's 2. 12β — meaning TMCI is approximately 237% more volatile than MASI relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -27. 1% for Masimo Corporation (MASI). On earnings-per-share growth, the picture is similar: Masimo Corporation grew EPS 51. 0% year-over-year, compared to -3. 3% for Treace Medical Concepts, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -27. 7% for Treace Medical Concepts, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -25. 5% for TMCI. At the gross margin level — before operating expenses — TMCI leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Masimo Corporation (MASI) trades at 32.

5x forward P/E versus 69. 8x for Stratasys Ltd. — 37. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SSYS: 64. 6% to $13. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Masimo Corporation (MASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

63), +282. 9% 10Y return). Treace Medical Concepts, Inc. (TMCI) carries a higher beta of 2. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MASI: +282. 9%, TMCI: -92. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RBOT (Healthcare) and ISRG (Healthcare) and MASI (Healthcare) and SSYS (Technology) and TMCI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RBOT is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; MASI is a small-cap quality compounder stock; SSYS is a small-cap quality compounder stock; TMCI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.